Business context and reporting period
uniQure N.V. is a clinical-stage gene-therapy company developing treatments for rare and other serious diseases. This unaudited Form 10-Q covers the three months ended March 31, 2021; amounts are in U.S. dollars. Its lead hemophilia B candidate, etranacogene dezaparvovec, was licensed to CSL Behring after the quarter, while the company continued developing AMT-130 for Huntington’s disease and other programs.
Financial results and liquidity
| Metric | Q1 2021 | Q1 2020 or comparison |
|---|---|---|
| Revenue | $0.5 million | $0.1 million |
| Research and development expense | $32.7 million | $26.0 million |
| Selling, general and administrative expense | $12.4 million | $9.1 million |
| Operating loss | $44.5 million | $34.5 million |
| Net loss | $41.6 million; $0.91 per share | $28.0 million; $0.63 per share |
| Net cash used in operating activities | $41.3 million | $33.0 million |
| Cash, cash equivalents and restricted cash at quarter-end | $263.5 million | $345.0 million at March 31, 2020 |
Revenue remained immaterial relative to operating costs; product sales had not begun. The filing does not present a meaningful gross margin. R&D costs rose 26% and SG&A costs rose 36% year over year, reflecting program, personnel, facility, share-based compensation and professional-fee increases. Net loss widened by $13.6 million. Foreign-currency gains of $4.6 million partly offset expenses; the prior-year period also included a $2.0 million gain on BMS warrants.
At March 31, 2021, cash and cash equivalents were $260.8 million, current assets $282.3 million, current liabilities $32.1 million, and total liabilities $135.2 million. Long-term debt was $70.5 million carrying value; principal outstanding was $70.0 million. The company reported $228.7 million of shareholders’ equity and an accumulated deficit of $826.3 million. Q1 financing generated $62.6 million, including $34.6 million net loan proceeds and $27.6 million net ATM proceeds. Investing used $3.9 million, mainly for facility expansion.
Material changes and significant developments
- Compared with Q1 2020, revenue increased by $0.35 million, but operating expenses increased by $9.95 million and net loss increased by $13.56 million.
- In January 2021, uniQure amended its Hercules debt facility, drew $35 million of a new $100 million tranche, and extended the interest-only period on existing debt to June 2023. Up to $65 million more could be drawn in qualifying advances through December 15, 2021. Debt is due June 2023, subject to extension options.
- The company sold 859,885 shares through its ATM program during Q1 for $27.6 million net proceeds. The program permits sales of up to $200 million in aggregate.
- The CSL Behring agreement became effective May 6, 2021, after quarter-end antitrust clearance; CSL paid the $450 million upfront payment on May 7. uniQure is also eligible for up to $1.6 billion in milestones and tiered double-digit royalties up to the low twenties as a percentage of net sales. Certain single-digit collaboration revenue is payable to licensors.
- On April 23, 2021, FDA lifted the clinical hold on the hemophilia B program following uniQure’s investigation of a possible hepatocellular carcinoma case in one trial participant. The company said its analyses indicated the cancer was highly unlikely to have been caused by the therapy.
- In April, uniQure settled a dispute involving former employees and VectorY. It expects to receive preference shares representing 5% of VectorY’s fully diluted share capital and entered a cooperation agreement with Forbion entities.
Outlook, commentary and risks
Management estimated that March 31 cash, the debt facility and the subsequent CSL upfront payment would fund operations into the second half of 2024, assuming full repayment of Hercules borrowings by 2023. Before the CSL payment, management estimated funding through the end of 2022 using March 31 cash and the facility. These estimates exclude potential milestone and royalty receipts; management expects continuing losses and negative cash flows beyond 2021. Expenses are expected to rise as clinical programs, research, staffing and manufacturing capabilities expand.
- uniQure remained responsible for completing the HOPE-B trial, manufacturing validation and supply of the hemophilia B product until transfer to CSL or its designee; CSL is responsible for global regulatory submissions and commercialization. Reimbursable CSL development expenses were recorded, but no CSL license revenue was recognized at March 31 because the agreement was not yet effective.
- HOPE-B interim results cited in the filing showed mean FIX activity of 37.2% at 26 weeks among 54 patients, an 83% reduction in total bleeding events and a 96% decline in mean annualized FIX replacement use versus the lead-in period. These are interim clinical results, not proof of approval or durable benefit.
- COVID-19 could disrupt trials, manufacturing, supply chains, staffing and regulatory timelines. Additional key risks include clinical safety or efficacy failures, manufacturing scale-up and validation, regulatory uncertainty, competition, intellectual-property dependence, reimbursement, and the need to manage debt and ongoing cash burn.
- The Hercules facility carries restrictive covenants and a security interest over substantially all assets, with specified cash-location requirements. The company reported material compliance with covenants at quarter-end. Debt and operating lease obligations totaled $144.1 million, including interest in the debt estimate.
- A $2.6 million Level 3 BMS contingent change-of-control liability is based on unobservable assumptions. A BMS payment may become due if specified change-of-control or target-cessation conditions occur. The company reported no off-balance-sheet arrangements.
- The filing states disclosure controls were effective and no material change in internal control over financial reporting occurred during Q1.
Important facts for investors to verify
- Receipt and use of the $450 million CSL payment, associated payments to licensors, tax effects and the resulting revised cash runway.
- Remaining CSL regulatory and commercial milestones, royalty terms, reimbursement arrangements and manufacturing-transfer responsibilities.
- Updated HOPE-B follow-up, regulatory filing timelines and safety monitoring after the FDA clinical hold was lifted.
- AMT-130 trial enrollment, safety findings and planned European study timing, as well as the cost and progress of other pipeline programs.
- Actual cash burn, future ATM share issuance and dilution, Hercules draw availability, repayment obligations and covenant compliance.
- Resolution and accounting for the VectorY settlement, the BMS contingent payment and any other contingencies or commitments.